Keane W, 124
Kean WF, 41
Kearns GL, 231
Kelloway JS, 1038
Khettab EN, 37
King S-YP, 558
Kinter LB, 163
Klamerus KJ, 716
Klein J, 338, 671
Knupp CA, 242
Koenig W, 539
Kohl RL, 163
Koren G, 338, 671
Kotegawa T, 157
Krol TF, 176
Kuhn K, 539
Kumar Y, 843

Lacourcière Y, 660
Laddu A, 434, 520
Laddu AR, 351
Lai M-L, 272
Lanctôt KL, 897
Landau SW, 141
Lang R, 711
Laporte-Simitsidis S, 990
Lasseter KC, 351
Lavie E, 546
Lazar EJ, 455
Lazar JD, 643
Lebsack ME, 91
Lee JW, 1003
Lefebvre J, 660
Lema G, 816
Lettieri JT, 571
Levêque D, 1096
Levin B, 61
Levin SL, 1013
Levine L, 476
Levine MAH, 1110
Lewanczuk RZ, 1105
Lewin A, 444
Lewis JA, 85
Liebman HA, 242
Locke C, 32
Louis WJ, 427
Luchsinger A, 55
Lueg M, 61
Lukacsko P, 463
Lum BL, 911

Magner DJ, 808
Malesker MA, 833
Maloney K, 716
Manning C, 996
Manning EJ, 996
Martin M, 476
Martin RR, 242
Martinelli L, 978
Martínez L, 1115
Masotto C, 1120
Materson BJ, 627
Mathias RJ, 1033
Maurath CJ, 434
Mauro LS, 476, 1054
Mauro VF, 1054
Mayersohn M, 412
Mayor GH, 1135
Mazzu AL, 571
McCluskey D, 61
McEntegart CM, 412
McHugh D, 376
McKenney JM, 277
McLaren C, 242
McNutt BE, 267
Medina MT, 28
Mehta AV, 1023
Mene M, 141
Menzel-Soglowek S, 944
Michael UF, 412
Mikati MA, 511
Mims M, 1008
Minn FL, 1089
Mismetti P, 990
Mitchell JE, 1060
Mitchell MS, 2
Mohiuddin SM, 833, 1033
Money KE, 163
Moos CD, 576
Morales N, 816
Morillo J, 55
Morris D, 647
Munger MA, 70
Munroe WP, 277

Nair R, 70
Nakano S, 157, 822
Nakashima H, 157
Nakayama I, 256
Nara AR, 70
Naranjo CA, 897
Nayak R, 1089
Nealley EW, 368
Negro-Villar A, 1120
Nelson RC, 400
Nerurkar SG, 935
Neu HC, 407, 685, 692, 804
Ngo WL, 415
Nipper HC, 833
Nitchuk WM, 953
Nitta Y, 256
Noble BG, 502
Nuchi Y, 816

Ochi T, 667
Ogawa N, 822
Ogilvie R, 338
Ohashi K, 1099
Ohashi K-i, 184, 838
Ohdo S, 822
Ohira H, 838
Ohishi M, 256
Okerholm RA, 267, 576
Okun R, 351
Olson SC, 344
Oosterhuis B, 470
Opsahl JA, 344
Otis J, 511

Pabst G, 553
Pai SM, 242
Pan H, 124
Park Y, 32
Parker S, 706
Passananti GT, 1128
Pasutto FM, 917
Paton TW, 1110
Patrick W, 450
Peck CC, 400
Pentikainen PJ, 136
Perpoint B, 990
Petit J-Y, 37
Pieniaszek HJ Jr, 412, 558
Piepho RW, 18
Pieretti OH, 55
Pieterson EA, 889
Piquette-Miller M, 148
Pittman KA, 242, 725, 798, 827
Poirier L, 660
Pool JL, 351
Posvar E, 1120
Posvar EL, 70, 344
Pouchus YF, 37
Powell JR, 176
Powell RJ, 558
Prescott AW, 70
Preston RA, 627
Prisant LM, 390, 610, 614, 620
Provencher P, 660

Queneau P, 990
Quoix E, 1096

Rachael K, 344
Radulovic LL, 91
Raines DA, 905
Raizada V, 351
Ramadan NM, 66
Rambaud C, 990
Rapoport AP, 486
Rasines C, 816
Regazzi MB, 978
Rhoades RB, 614
Rice PJ, 1023
Rischke J, 41
Robert S, 66
Roberts CJC, 284
Robieux I, 338
Rofman BA, 360
Rogers JD, 136
Rogers W, 390
Rolf CN, 576
Romero E, 55, 816
Rondanelli R, 978
Rosenthal J, 539
Roser R, 1115
Rossiter K, 536
Rotenberg Z, 639
Rotschafer JC, 1083
Rowe JM, 486
Ruberg SJ, 267
Rubinstein E, 711
Rudolph RL, 716
Ruoff GE, 360
Russell AS, 982

Sacher HL, 141
Sacher ML, 141
Sagarra R, 1115
Sallman AL, 415
Sanchez M, 28
Saraheimo M, 136
Sánchez J, 1115
Scandale L, 996
Scarpinato L, 18
Schary WL, 558
Scheel PJ Jr, 536
Schneiderman N, 564, 604
Schoemaker HC, 324
Schumacher GE, 1141
Schwartz JI, 136
Schwartz MS, 136
Sedman AJ, 91
Seidler NW, 332
Shah VR, 798
Shapiro B, 124
Shapiro BE, 1038
Shear NH, 897
Shepard KV, 1003
Shiga T, 838
Shukla UA, 242, 725
Shyu WC, 798
Simonson MS, 70
Sisenwine SF, 716
Sitar DS, 24
Skeith KJ, 982
Somberg JC, 1, 99, 195, 295, 389, 485, 546, 583, 679, 773, 843, 867, 963, 1059
Soons PA, 324
Sostrin MB, 827
Sotelo J, 28
Sowers JR, 529
Steigerwalt SP, 66
Steiner C, 61
Stellar S, 1089
Stewart JJ, 1008
Stoysich AM, 833
Stringer KA, 91
Ström M, 49
Sullivan TJ, 476
Sumimoto T, 667
Swislocki NI, 332
Szabo GK, 1141

Takase K, 256
Tallman MS, 868
Tam J, 911
Tateishi T, 1099
Tay LK, 827

Thalken LJ, 1033
Theodor R, 553
Thien T, 652
Thieneman AC, 571
Thompson GA, 210
Tremaine LM, 643
Trenk D, 77
Triscari J, 124
Troendle A, 630
Tsai J-J, 272
Tse FLS, 630
Tsutsumi K, 157

Urbina A, 55

Valentine FT, 242
Vance-Bryan K, 1083
Velasco M, 55, 816
Verbist J-F, 37
Vesell ES, 1128
Vesely DL, 415
Vestal RE, 779
Vigano' M, 978
Vlachakis ND, 351
Vogel GW, 647
von Deutsch DA, 643
von Dohlen T, 390

Wagner A, 816
Walker BJ, 267
Walker KJ, 1083
Walker SE, 1110
Wallin JD, 444
Watson A, 536
Wechter WJ, 915, 955
Wedlund PJ, 107
Weidler D, 444
Weidler DJ, 564
Weinberger I, 639
Welin L, 37
Westmark PA, 267
Whelton A, 536, 808
White WB, 524
Wiegand A, 77
Wiernik PH, 868
Wilber RB, 798
Williams EMV, 964
Williams MA, 1033
Williams RL, 360, 597, 935
Wilner KD, 222, 643
Wilson DS, 32, 1045
Wilson JT, 231
Winters CJ, 415
Wollersheim H, 652
Wombolt DG, 351
Wood CD, 1008
Wood MJ, 1008
Wooles WR, 502
Wright JT Jr, 277
Wyeth RP, 415

Yamaji E, 256
Yang Y-HK, 272
Yee JP, 376

Zabinski RA, 1083
Zaborny BA, 463
Zawada ET, 310
Zborowska-Sluis D, 338
Ziemniak JA, 463
Zlotikamien B, 639
Zuiderwijk PBM, 470

Subject Index, Volume 32 (1992)

Absorption
beta-emthyldigoxin, influence of food on, 157
gepirone, gastrointestinal site of, 827
levothyroxine absorption from Synthroid and Levoxine in normal volunteers, 1135
methyldopa, after multiple doses, 450
Acebutolol enantiomers
pharmacokinetics of, aging and, 148
pharmacokinetics of, effects of arthritis on, A753
ACE-Inhibitors
antiischemic action in coronary artery disease, A742
Acetaminophen
amantadine hydrochloride effects on pharmacokinetics, 24
pharmacokinetics in febrile children, 231
Acetazolamide
plasma protein binding and renal clearance, albumin infusion for elucidating relationship between, 1028
Acquired immunodeficiency syndrome
ceftriaxone in nocardiosis in, A763
didanosine plasma concentrations in patients with, 242
Acyclovir
cytomegalovirus infection prevention after liver transplantation, A753
Adverse Drug Effects
diagnosis of, 897
heparin, 584
oral anticoagulants, 196
terazosin, effect of age and dose on incidence in hypertension, 434
AIDS-Related Complex
didanosine plasma concentrations in patients with, 242
Alacepril
left ventricular hypertrophy and function in essential hypertension, 667
Albendazole
in brain cysticercosis, 28
Allergic Rhinitis
seasonal, astemizole and terfenadine in, onset of action of, A761
Alpha-1-Acid Glycoprotein
in depression, antidepressant binding and, A764
Alpidem
benzodiazepine binding of, A764
Alprazolam
fluoxetine and norfluoxetine inhibition of, A764
Altered Mental Status
in nineteen-year-old man, 511
Alzheimer's Disease
HP 749 as potential therapeutic in, A752
Amantadine
acetaminophen pharmacokinetics in young adults, 24
pharmacokinetics in young adults, 24
Ambulatory Blood Pressure
antihypertensive agent assessment, 524
hypertensive evaluation and management using, outcome and cost effectiveness and, 610
nebivolol and nifedipine sustained-release effects, 660
ramipril effects on, A747
target organ complications and equipment choices, clinical utility in, 620
Amiodarone
in inducible ventricular tachycardia, A743
Amphotericin B
single-dose intravenous, in candidal urinary tract infections, A750
Analytical Methods
digibind effects on digoxin concentrations, comparison with FPIA and ELIA methods, A754
hair analysis of cocaine, 671
internal standard amount and precision of, 676
nortriptyline serum concentrations, sources of prediction error using Bayesian method to analyze, A753
pentoxifylline determination by high performance liquid chromatography, A752
theophylline saliva and serum concentrations, A754
Angina
epanolol for assessing patient preference in antianginal drug therapy, 85
hypothyroidism complicated by angina pectoris, therapeutic approaches to, 843
nifedipine alone and in combination with dilazep in, A746
nitroglycerine in, A747
unstable, pharmacotherapy of, 390
Ankyrin
isoform heterogeneity in cultures of cortex, hypothalamus, and dorsal root ganglion demonstrated by anti-ankyrin monoclonal antibodies, A765
Antacids
droxicam pharmacokinetics and, 1115
Anti-Arrhythmic Drugs
amiodarone in inducible ventricular tachycardia, A743
beta-blockers added to in inducible sustained ventricular tachycardia, A743
bidisomide pharmacokinetics, A749
classification of actions of, 969
defibrillation energy requirements during therapy with, A744
isoproterenol effects and utility in patients who partially respond to antiarrhythmic drug therapy, A743
Antibiotics
beta-lactam, in once-daily oral therapy, 711
Anticoagulants
oral, pharmacodynamics, clinical indications and adverse effects, 196
Antidepressant Drugs
alpha-1-acid glycoprotein binding in depression and, A764
Antiemetic Agents
dacarbazine-induced emesis, combination antiemetic regimen in, A760
dronabinol in chemotherapy-induced delayed emesis, A760
Antihistamines
meclizine and dimenhydrinate effects on central nervous system, 996
Antihypertensive Agents
alacepril effects on left ventricular hypertrophy and function in essential hypertension, 667

ambulatory blood pressure monitoring for assessment of, 524
atenolol, antihypertensive and metabolic effects of single and combined regimens, 61
atenolol, metoprolol, chlorthalidone, verapamil, and atenolol-chlorthalidone combination in office and ambulatory settings, 564
beta-blocking drug effects on peripheral circulation in Raynaud's phenomenon and hypertension, 652
cerebral blood flow velocity effects of, 66
circadian blood pressure pattern and, 627
diltiazem, once-daily versus twice-daily, efficacy of, A742
diltiazem SR, sustained activity of, 808
dopaminergic agonist effects on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients, 55
hippocampal dynorphin system, A745
nebivolol and nifedipine sustained-release effects on 24-hour ambulatory blood pressure and plasma lipoproteins, 660
nisoldipine coat-core tablet pharmacokinetics and pharmacodynamics in hypertensive patients, A754
nisoldipine pharmacokinetics, 571
terazosin, effect on blood pressure and urinary output of dopamine in hypertensive patients, 816
transcranial Doppler to evaluate effects on cerebral blood flow velocity, 66
verapamil and nifedipine in mild to moderate hypertension, A744

Anti-Infective Agents
albendazole pharmacokinetics in patients with brain cysticercosis, 28
amantadine hydrochloride, effects on its and acetaminophen pharmacokinetics in young adults, 24
cefpiromine pharmacokinetics in healthy volunteers, 256
cefpodoxime proxetil disposition in hemodialysis patients, 1038
cefprozil oral absolute bioavailability and intravenous dose-proportionality, 798
clarithromycin drug-food interaction, 32
clarithromycin pharmacokinetics in healthy young and elderly volunteers, 1045
C-5 methyl fluoroquinolone plasma bactericidal activity, 804
didanosine plasma concentrations in patients with AIDS or AIDS-related complex, 242
pathogen evolution in vulvovaginal candidiasis, 248

Anti-Inflammatory Agents
cordiachromene A stereospecific anti-inflammatory activity, 37
flurbiprofen pharmacokinetics in younger and elderly patients with rheumatoid arthritis, 41
ibuprofen and acetaminophen single-dose pharmacokinetics in febrile children, 231
tenidap effects on pharmacokinetics and pharmacodynamics of prednisolone, 222
tranexamic acid pharmacokinetics in patients with ulcerative colitis and healthy volunteers, 49

Antimicrobials
activity and pharmacology, 407
once-daily oral therapy, beta-lactam antibiotics in, 711
once-daily oral therapy, controversy over, 685
once-daily oral therapy, cost effectiveness of, 706
once-daily oral therapy, experience with, 686
once-daily oral therapy, fluoroquinolones in, 692
once-daily oral therapy, preclinical data needed to justify, 698

Antimotion Sickness Drugs
intramuscular, effectiveness and duration of, 1008
in squirrel monkey, 163

Antiparkinsonian Drugs
in chronic schizophrenics receiving dopamine antagonists, need for, A766
hypoglycemia caused by, A767

Arrhythmias. See *also* **Anti-Arrhythmic Drugs**
coronary occlusion, effects of age on, A746

Arthritis
acebutolol enantiomer pharmacokinetics and, A753
paracetamol with central analgesics in osteoarthritis, 990
rheumatoid, flurbiprofen pharmacokinetics in younger and elderly patients with, 41

Aspirin
hydrolysis in patients with atherosclerosis, 133
pharmacokinetics of ibuprofen/aspirin interaction on anti-platelet activity, A750

Astemizole
in seasonal allergic rhinitis, onset of action of, A761
sedative properties in healthy volunteers, A750

Asthma
triamcinolone acetonide aerosol in, 463

Atenolol
antihypertensive and metabolic effects of single and combined regimens, 61
in office and ambulatory settings, 564

Atherosclerosis
aspirin hydrolysis and platelet aggregation in patients with, 133
drug development for ischemic heart disease and, 848
fluvastatin pharmacokinetics after single and multiple doses in normal volunteers, 630
insulin resistance, dyslipidemia, hyperinsulinemia and hypertension and, 529
lovastatin, simvastatin and pravastatin pharmacokinetics, 136
pravastatin and metabolite pharmacokinetics in patients with renal impairment, 124

Atrial natriuretic factor
pharmacokinetics during and after rapid right ventricular pacing in dogs, 415
verapamil and volume overload effects on, 1120

Automated blood pressure monitoring, 603
antihypertensives and circadian blood pressure pattern and, 627
ethnicity and, 604
manual office pressures and, variability and similarity of, 614

Baclofen
pharmacokinetics and pharmacodynamics in spinal cord injury, A748

Bacterial Infections
pharmacotherapy and pharmacodynamics in management of, 1083

Benign Prostatic Hyperplasia
terazosin in, quality of life assessment and, A760
terazosin safety and efficacy in, A759, A762

Benzafibrate
simvastatin with, in healthy subjects, 422

Benzodiazepines
alpidem, zolpidem, and zopiclone binding by, A764
prenatal exposure and inverse agonist efficacy in mature mice, A764
receptor distribution and, advancing age and, A765

Beta-2-Adrenergic Drugs
pharmacokinetics and pharmacodynamics of, A752

Beta-Blocking Drugs
adding to antiarrhythmic drugs in inducible sustained ventricular tachycardia, A743
peripheral circulation in Raynaud's phenomenon and hypertension, 652

Beta-Emthyldigoxin
influence of food on absorption of, 157

Beta-Lactam Antibiotics
in once-daily oral therapy, 711

Betaxolol
in hypertension, dose-dependent effects of, 360

Bidisomide
pharmacokinetics of, A749

Bioavailability. See **Pharmacokinetics**

Bioequivalence. See **Chirality**

Biomedical Research
industry-university alliances in, 100

Biomodulators
in cancer treatment, 2

Blood pressure monitoring. See **Ambulatory blood pressure; Automated blood pressure monitoring**

Book Reviews
Clinical Drug Therapy, 769
The Design of Analgesic Clinical Trials, 768
Drugs in Gastroenterology, 768
Excitatory Amino Acids, 768
Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis, 768
Patient Compliance in Medical Practice and Clinical Trials, 769
Retinoids: 10 Years On, 768

Brain. *See also* **Central Nervous System Agents**
albendazole in neurocysticercosis, 28
ankyrin isoform heterogeneity in cultures of cortex, hypothalamus, and dorsal root ganglion demonstrated by anti-ankyrin monoclonal antibodies, A765
deposition of fluphenazine and its metabolites in rat brain, A766
meclizine and dimenhydrinate effects on central nervous system, 996
praziquantel in neurocysticercosis, one-day dosage regimen for, A762

Busipirone
in premenstrual syndrome, efficacy and pharmacologic mechanism of, A748

Caffeine
diurnal effect on clearance of, 184

Cancer Treatment
biomodulators in, 2
dronabinol in chemotherapy-induced delayed emesis, A760
emesis induced by, combination antiemetic regimen in, A760
retinoids in, 868

Captopril
cGMP level elevation in vascular muscle, A746

Cardiac Transplantation
digoxin pharmacokinetics, 338

Cardiovascular System
acebutolol enantiomer pharmacokinetics, aging and, 148
acetazolamide plasma protein binding and renal clearance, albumin infusion for elucidating relationship between, 1028
benzafibrate-simvastatin in healthy subjects, 422
beta-emthyldigoxin absorption, influence of food on, 157
cardiac transplantation and cyclosporine therapy effects on digoxin pharmacokinetics, 338
cimetidine effect on pirmenol pharmacokinetics, 91
dipyridamole and thallium myocardial imaging, 546
dobutamine, outpatient therapy with, 141
dopaminergic agonist effects on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients, 55
encainide bioavailability, effect of food on, 833
epanolol as disease model for assessing patient preference in anti-anginal drug therapy, 85

furosemide chronopharmacology in elderly patients, 838
glyceryl trinitrate time-dependent release, pharmacodynamic and pharmacokinetic evaluation of, 77
H_2-antagonist therapy, effect on left ventricular systolic function and exercise capacity, 1033
H_2-receptor antagonist effects on, A746
hypothyroidism complicated by angina pectoris, therapeutic approaches to, 843
isosorbide-5-mononitrate bioavailability and pharmacokinetics in healthy volunteers, 553
moricizine effects on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers, 558
moricizine pharmacokinetics in renal insufficiency, 412
naldolol pharmacokinetics in children with supraventricular tachycardia, 1023
nifedipine pharmacokinetics and effects in healthy subjects, intraindividual variability in, 324
pentoxifylline effects on plasma membrane Ca^{2+} ATPase in age-separated rat and human erythrocytes, 332
prohormone atrial natriuretic peptides amino acids 1-98, 31-67, and atrial natriuretic factor pharmacokinetics during and after rapid right ventricular pacing in dogs, 415
quinapril effects on regional blood flow and cardiac function in patients with congestive heart failure, 70
Synthroid ingestion presenting as congestive heart failure, 18
Cefpiromine
pharmacokinetics in healthy volunteers, 256
Cefpodoxime Proxetil
in hemodialysis patients, disposition of, 1038
Cefprozil
oral absolute bioavailability and intravenous dose-proportionality, 798
pharmacokinetic interactions with food, propantheline, metoclopramide, and probenecid in healthy volunteers, 725
Ceftriaxone
in nocardiosis in AIDS patients, A763
Central Nervous System Agents
antimotion sickness drugs, intramuscular, effectiveness and duration of, 1008
antimotion sickness drugs in squirrel monkey, 163
classical and nontraditional parasympatholytic agents, salivatory responses to, 1013
estazolam effects on sleep, performance, and memory, 647
gepirone absorption, gastrointestinal site of, 827
sertraline and steady-state concentrations or renal clearance of lithium in healthy volunteers, 643
terfenadine pharmacokinetics in healthy elderly subjects, 267
valproate kinetics, circadian changes depending on meal condition and, 822
verapamil, diltiazem and labetalol effects on bioavailability and metabolism of imipramine, 176
Cerebral Blood Flow
antihypertensive medication, evaluation of effects on cerebral blood flow velocity, 66
Children
ibuprofen and acetaminophen pharmacokinetics in, 231
naldolol pharmacokinetics in children with supraventricular tachycardia, 1023
naproxen tablet and suspension pharmacokinetics in, A758
Chirality
2-arylproprionic acid enantiomers, 944
drug action and disposition, 925
enantiomers, 917
racemic drug bioequivalency, 915, 935, 955
regulatory requirements for generic chiral drugs and, 953
stereochemisty and bioequivalence and, 930
Chlorthalidone
in office and ambulatory settings, 564
Cholecystectomy
stereoselective pharmacokinetics after, 982
Cholestyramine
hyperchloremic metabolic acidosis induced by, 536
sulindac pharmacokinetics and, A754
valproic acid serum concentrations and, A754
Chronic Obstructive Pulmonary Disease
nizatidine, ranitidine, and cimetidine effects on pharmacokinetics of theophylline in, 476
CI-981
lipid response Alzheimer's disease function of dosing time, A749
multiple-dose tolerance and pharmacologic effect, A749
Cimetidine
pirmenol pharmacokinetics, effects on, 91
propranolol metabolism and, 1099
theophylline pharmacokinetics in COPD, 476
Cirrhosis
nifedipine sustained-release tablet steady-state pharmacokinetics, A757
Cisplatin
subcellular biodistribution in tumored rats, A747
vinorelbine combined with, pharmacokinetics of, 1096
Clarithromycin
drug-food interaction, 32
pharmacokinetics in healthy young and elderly volunteers, 1045
Clinical Pharmacology
case conference approach to teaching, 502
clinical pharmacology training at the Food & Drug Administration, 400
Clinical Therapeutic Conference
altered mental status in a nineteen-year-old man, 511
antimicrobial activity and pharmacology, 407
geriatrics nephrology, 310
grand mal status epilepticus, 215
management of menopausal and postmenopausal women, 774
pharmacokinetic principles in clinical medicine, 118
Synthroid ingestion presenting as congestive heart failure, 18
ventricular dilation control in compromised myocardium, 680
Clonidine
slow-release and conventional formulation after acute and chronic administration in hypertension, 427
transdermal, as adjunct to enalapril in hypertension, 444
C-5 Methyl Fluoroquinolone
plasma bactericidal activity, 804
Cocaine
hair analysis, 671
Codeine
paracetamol with, in osteoarthritis, 990
Computerized Study and Review Programs, 10
Congestive Heart Failure
quinapril effects on regional blood flow and cardiac function in patients with, 70
Synthroid ingestion presenting as, 18
Cordiachromene A
stereospecific anti-inflammatory activity, 37
Coronary Artery Disease
ACE-inhibitor antiischemic action in, A742
Cyanide Poisoning
sodium nitrate and sodium thiosulfate antidotal action against, 368
Cyclosporin-A
pharmacokinetic parameters for, arithmetic versus harmonic mean values for, 911
Cyclosporine
digoxin pharmacokinetics, 338
monitoring in transplant patients, optimization of sampling time for, 978
Cytarabine
etoposide combined with, lowering of intracellular cytosine-arabinoside-triphosphate formation by, A759
Cytomegalovirus Infection
ganciclovir versus acyclovir in prevention of, following liver transplantation, A753

Dacarbazine
emesis induced by, combination antiemetic regimen in, A760
Dental Pain
keterolac and meperidine in relief of, efficacy and safety of, 376
Depression
alpha-1-acid glycoprotein in, antidepressant binding and, A764
drug-induced, in young and elderly hypertensive patients, A765
Desipramine
metabolism of, pharmacogenetics of, A765
Dextropropoxyphene
paracetamol with, in osteoarthritis, 990
Diabetes Mellitus
drug binding kinetics in type I diabetes, A759
N-acetylation polymorphism and, among Saudi Arabians, 905
oral hypoglycemia agents in type II diabetes, A761
Diazepam
anti-hypoxia mechanism of, A766
Didanosine
plasma concentrations in patients with AIDS or AIDS-related complex, 242
Digibind
digoxin concentration effects of, comparison with FPIA and ELIA methods, A754
Digoxin
cardiac transplantation and cyclosporine therapy effects on pharmacokinetics of, 338
digibind effects on concentration of, comparison with FPIA and ELIA methods, A754
Dilazep
in angina pectoris, A746
Diltiazem
imipramine bioavailability and metabolism, 176
once-daily versus twice-daily, antihypertensive efficacy of, A742
propranolol metabolism and, 1099
sustained antihypertensive activity of diltaizem SR, 808
Dimenhydramate
central nervous system effects of, 996
Dipyridamole
oral suspension formulation, thallium myocardial imaging and, 546546
Distinguished Investigator Award
propionic acids, 317
Dobutamine
outpatient therapy with, 141
Dopamine
renal function effects of, A742
terazosin and urinary output of, in hypertensive patients, 816
Dopamine Antagonists
in chronic schizophrenia, need for antiparkinsonian drugs and, A766
Dopaminergic Agonists
cardiovascular, renal, and renin-angiotensin system effects in hypertensive patients, 55

comparative effects on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients, 55
Dosage Regimen Design, 210
pharmacokinetics, 597
Dronabinol
in chemotherapy-induced delayed emesis, A760
Droxicam
pharmacokinetics of, effect of antacid and ranitidine on, 1115
Drug Development, 485
centralized, 583
for ischemic heart disease, atherosclerosis and, 848
Drug-Food Interactions
beta-emthyldigoxin, 157
cefprozil, 725
clarithromycin, 32
encainide bioavailability, effect of food on, 833
fenretinide bioavailability, effects of meals and meal composition on, 1089
ibuprofen enantiomers, bioavailability of, 1110
morphine sulfate bioavailability after multiple doses of sustained-release tablets, effect of food on, 1003
Drug Interactions
prednisolone and hydrocortisone, A756
Dyslipidemia
insulin resistance, hyperinsulinemia, hypertension and accelerated atherosclerosis and, 529

Editorial (title)
Are We on Course?, 99
To Board or Not, 679
Centralized Drug Development, 583
Clinical Pharmacology: Medicine of Pharmacology, 773
Has the Promise Been Kept?, 1
The Pendulum Swings, 195
Pharmaceutical Costs, 1059
Physicians in Industry, 389
Sharing Regulatory Review Costs, 867
On Stronger Footing, 295
Thoughts from the Editor, 963
Thoughts on Drug Development, 485
Education
case conference approach to teaching clinical pharmacology, 502
clinical pharmacology teaching to prepare students for primary care rural practice, A760
clinical pharmacology training at the Food & Drug Administration, 400
computerized study and review programs, 10
legal curriculum for clinical pharmacologists, order of precedence of authority and, 1073
workshop on problem-based learning as method for teaching clinical pharmacology and therapeutics in medical school, 779
Elderly Patients
acebutolol enantiomer pharmacokinetics, 148
drug-induced depression in, A765
flurbiprofen pharmacokinetics in younger and elderly patients with rheumatoid arthritis, 41
furosemide chronopharmacology in, 838
geriatrics nephrology, 310
labetalol in, myocardial function and exercise response changes with increasing age and, A747
terfenadine pharmacokinetics in, 267
Electrocardiography
pentamidine effects on, A743
Electronic Medication Compliance Aid
long-term blood pressure control and, 277
Enalapril
transdermal clonidine as adjunct to, in hypertension, 444
Enantiomers
of acebutolol, effects of arthritis on pharmacokinetics of, A753
of acebutolol, pharmacokinetics of, aging and, 148
analysis of, 917
of 2-arylproprionic acid, 944
of ibuprofen, effect of food or sucralfate on bioavailability of, 1110
of sotalol, pharmacokinetics of, 1105
Encainide
effect of food on bioavailability of, 833
Epanolol
in anti-anginal drug therapy, as disease model for assessing patient preference in, 85
Epilepsy
grand mal status epilepticus, 215
lamotrigine in refractory partial seizures, efficacy and safety of, A766
Erythropoietin
in end stage renal disease, dosing, response to, and effectiveness of, A758
Estazolam
sleep, performance, and memory effects of, 647
Etodolac
stereoselective pharmacokinetics in young and elderly subjects, after cholecystectomy, 982
Etoposide
cytarabine combined with, lowering of intracellular cytosine-arabinoside-triphosphate formation by, A759

Fenretinide
bioavailability of, effects of meals and meal composition on, 1089
Fluoroquinolones
in once-daily oral therapy, 692
Fluoxetine
alprazolam inhibition by, A764
Fluphenazine
deposition of fluphenazine and its metabolites in rat brain, A766
Flurbiprofen
pharmacokinetics and anabolic bone response in rat, A758
pharmacokinetics in younger and elderly patients with rheumatoid arthritis, 41
Fluvastatin
pharmacokinetics after single and multiple doses in normal volunteers, 630
Food. *See* **Drug-Food Interactions**
Furosemide
chronopharmacology in elderly patients, 838

Gabapentin
disposition in hemodialysis patients, A751
Gallium Nitrate
pharmacokinetics, A748
Ganciclovir
cytomegalovirus infection prevention after liver transplantation, A753
pharmacokinetics in liver transplantation patients, A753
Genetics
drug disposition and therapeutics, 107
pharmacogenetics of desipramine metabolism, A765
Gepirone
gastrointestinal site of absorption of, 827
Glyceryl Trinitrate
time-dependent release, pharmacodynamic and pharmacokinetic evaluation of, 77

H_2 Antagonists
cardiovascular effects of, A746
H_2-Antagonists
left ventricular systolic function and exercise capacity and, 1033
Headache
isosorbide-5-mononitrate pharmacokinetics and, in healthy men, A754
Hematologic Agents
pentoxifylline, lack of effect on red blood cell deformability, 1050
pentoxifylline and prostaglandin E_2 and survival of, A763
pentoxifylline determination by high performance liquid chromatography, A752
pentoxifylline effects on plasma membrane Ca^{2+} ATPase in age-separated rat and human erythrocytes, 332
pentoxifylline pharmacokinetics in smokers and nonsmokers, 1054
Hemodialysis
cefpodoxime proxetil disposition and, 1038
gabapentin disposition and, A751
urokinase in central venous dialysis access malfunction, continuous infusion of, A757
Heparin
intravenous, endogenous periodicity of response to, A756
pharmacokinetics, clinical indications, and adverse effects, 584
Hippocampal Dynorphin System
antihypertensive agent strategy and, A745
Histamine Antagonist
hemodynamic actions during endotoxemia induced sepsis, A745
HP 749
safety, tolerability, and pharmacokinetics in healthy young men, A752
Hydrocortisone
pharmacokinetic interactions with prednisolone, A756
Hyperinsulinemia
insulin resistance, dyslipidemia, hypertension and accelerated atherosclerosis and, 529
Hyperlipidemia
big platelets in hyperlipidemic patients, 639
Hyperlipoproteinemia
lovastatin and blood rheology in primary hyperlipoproteinemia, 539
Hypertension. *See also* **Anti-Hypertensive Agents**
alacepril in essential hypertension, 667
beta-blocking drug effects on peripheral circulation in, 652
betaxolol in, dose-dependent effects of, 360
clonidine, slow-release and conventional formulation after acute and chronic administration in, 427
dopaminergic agonist effects on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients, 55
drug-induced depression and, A765
electronic medication compliance aid impact on long-term blood pressure control, 277
evaluation and management using, outcome and cost effectiveness and, 610
insulin resistance, dyslipidemia, hyperinsulinemia and accelerated atherosclerosis and, 529
labetalol in, myocardial function and exercise response changes with increasing age and, A747
methyldopa absorption and renal excretion after multiple doses, 450
nisoldipine pharmacokinetics, 571
nitrendipine and renal tubular function in human volunteers, 284
terazosin, effect of age and dose on incidence of adverse effects in hypertension, 434
terazosin and methyclothiazide in essential hypertension, concomitant administration of, 351
terazosin blood pressure response and safety in, A744
transdermal clonidine as adjunct to enalapril in hypertension, 444
verapamil, sustained-release formulations for, 455
verapamil combined with nifedipine in, A744

Hypoalphalipoproteinemia
nicotinic acid in isolated hypoalphalipoproteinemia, A745
Hypoglycemia
antiparkinsonian drug causing, A767
Hypothyroidism
angina pectoris complicating, therapeutic approaches to, 843

Ibuprofen
enantiomers of, effect of food or sucralfate on bioavailability of, 1110
pharmacokinetics in febrile children, 231
pharmacokinetics of ibuprofen/aspirin interaction on anti-platelet activity, A750
Imipramine
verapamil, diltiazem and labetalol effects on bioavailability and metabolism of, 176
Immunosuppressive Agents
cyclosporin-A pharmacokinetic parameters, arithmetic versus harmonic mean values for, 911
cyclosporine monitoring in transplant patients, optimization of sampling time for, 978
cyclosporine therapy effects on digoxin pharmacokinetics, 338
Insulin
insulin resistance, hyperinsulinemia, dyslipidemia, hypertension and accelerated atherosclerosis and, 529
lipoidal-erythrocyte, intraduodenal administration in rats, A761
Ischemic Heart Disease
drug development for, atherosclerosis and, 848
silent, nitroglycerine in angina and, A747
Isoproterenol
effects and utility in patients who partially respond to antiarrhythmic drug therapy, A743
Isosorbide-5-Mononitrate
bioavailability and pharmacokinetics in healthy volunteers, 553
pharmacokinetics, headache in healthy men and, A754

Jaundice
plasma surface tension in, A761

Ketanserin
aqueous humor dynamics in renal patients, A756
Keterolac
in dental pain, efficacy and safety in relief of, 376
Ketoprofen
renal disease effects on disposition of, A751

Labetalol
imipramine bioavailability and metabolism, 176
myocardial function and exercise response changes with increasing age and, A747
Lamotrigine
in refractory partial seizures, efficacy and safety of, A766
Left Ventricular Function
alacepril in essential hypertension, 667
H_2-antagonist therapy and, 1033
Leukemia
new drugs in acute myelogenous leukemia, 296
Levothyroxine
absorption from Synthroid and Levoxine in normal volunteers, 1135
Levoxine
levothyroxine absorption from, 1135
Lipid-Lowering Drugs
cholestyramine-induced hyperchloremic metabolic acidosis, 536
lovastatin and blood rheology in primary hyperlipoproteinemia, 539
Lipoproteins
nebivolol and nifedipine sustained-release effects on plasma levels of, 660
Lithium
sertraline and steady-state concentrations or renal clearance of lithium in healthy volunteers, 643
Liver Disease
nefazodone pharmacokinetics in healthy volunteers and hepatic impairment, A756
nifedipine sustained-release tablet steady-state pharmacokinetics, cirrhosis and, A757
Liver Transplantation
ganciclovir pharmacokinetics following, A753
ganciclovir versus acyclovir in prevention of cytomegalovirus infection following, A753
Lorazepam
single-dose bioavailability of solution and tablet formulations, A748
Lovastatin
blood rheology in primary hyperlipoproteinemia, 539
pharmacokinetics, 136

Meclizine
central nervous system effects of, 996
Menopause
management of menopausal and postmenopausal women, 774
Meperidine
in dental pain, efficacy and safety in relief of, 376
Metabolic Acidosis
cholestyramine-induced, 536
Metformin
bioavailability in tablet form, A757
Methyclothiazide
in essential hypertension, concomitant administration of terazosin and, 351
Methyldopa
absorption and renal excretion after multiple doses, 450
Metoclopramide
pharmacokinetic interactions with cefprozil, 725
Metoprolol
in office and ambulatory settings, 564
Moricizine
defibrillation energy requirements during therapy with, A744
pharmacokinetics in renal disease, A749
pharmacokinetics in renal insufficiency, 412
pharmacokinetics in young and healthy subjects, A754
warfarin pharmacokinetics and pharmacodynamics in healthy volunteers, 558
Morphine
morphine sulfate bioavailability after multiple doses of sustained-release tablets, effect of food on, 1003
morphine sulfate compatibility with enteral feeding products, A759
steady state levels, spreadsheet program for determination of variable infusion rates to produce stepwise changes of, A757

N-Acetylation Polymorphism
diabetes mellitus and, among Saudi Arabians, 905
Naftopidil
aqueous humor dynamics in renal patients, A756
Naldolol
pharmacokinetics in children with supraventricular tachycardia, 1023
Naproxen
gastroduodenal mucosal damage induced by, protective effect of PF 5901 against, A763
pharmacokinetics of tablets and suspension in children, A758
Nebivolol
ambulatory blood pressure and plasma lipoproteins and, 660
Nefazodone
pharmacokinetics in healthy volunteers and hepatic impairment, A756
Neurocysticercosis
albendazole in patients with, 28
praziquantel in, one-day dosage regimen for, A762
Nicoderm
plasma nicotine concentrations after application to different skin sites, 576
Nicotinic Acid
in isolated hypoalphalipoproteinemia, A745
Nifedipine
ambulatory blood pressure and plasma lipoproteins and, 660
in angina pectoris, A746
in mild to moderate hypertension, A744
pharmacokinetics and effects in healthy subjects, intraindividual variability in, 324
pharmacokinetics of sustained-release tablets, cirrhosis and, A757
verapamil combined with, in hypertension, A744
Nisoldipine
pharmacokinetics, 571
pharmacokinetics and pharmacodynamics of coat-core tablets in hypertensive patients, A754
Nitrendipine
renal tubular function in human volunteers, 284
Nitroglycerine
in angina, A747
Nizatidine
dose dependence of negative chronotropic effect of, A745
theophylline pharmacokinetics in COPD, 476
Nocardiosis
ceftriaxone in, in AIDS patients, A763
Norfluoxetine
alprazolam inhibition by, A764
Nortriptyline
serum concentrations, sources of prediction error using Bayesian method to analyze, A753

Omeprazole
theophylline elimination kinetics, 470
Opiate Antagonists
eating behavior and, 1060
Oral Anticoagulants
pharmacodynamics, clinical indications and adverse effects, 196
Oral Hypoglycemia Agents
in type II diabetes mellitus, A761
Organ Transplantation
cardiac, digoxin pharmacokinetics, 338
cyclosporine monitoring in transplant patients, optimization of sampling time for, 978
liver, ganciclovir pharmacokinetics following, A753
liver, ganciclovir versus acyclovir in prevention of cytomegalovirus infection following, A753
Osteoarthritis
paracetamol with central analgesics in, 990

Pain
2-arylproprionic acid enantiomers and, 944
Paracetamol
with central analgesics in osteoarthritis, 990
Parasympatholytic Agents
classical and nontraditional, salivatory responses to, 1013
Pentamidine
electrocardiographic effect, A743
Pentoxifylline
high performance liquid chromatography determination of, A752
pharmacokinetics in smokers and nonsmokers, 1054
plasma membrane Ca^{2+} ATPase in age-separated rat and human erythrocytes, 332
red blood cell deformability, lack of effect on, 1050

skin flap survival and, A763
PF 5901
protective effect against naproxen-induced gastroduodenal mucosal damage, A763
Pharmacodynamics
baclofen in spinal cord injury, A748
in bacterial infection management, 1083
of beta-2-adrenergic drugs, A752
glyceryl trinitrate time-dependent release, 77
nisoldipine coat-core tablets in hypertensive patients, A754
oral anticoagulants, 196
prednisolone, tenidap effects on, 222
prednisolone after intravenous and oral administration, A750
tandospirone, ascending single doses in healthy volunteers, A751
Pharmacokinetics
acebutolol, effects of arthritis on, A753
albendazole in patients with brain cysticercosis, 28
amantadine hydrochloride effects on its and acetaminophen pharmacokinetics in young adults, 24
baclofen in spinal cord injury, A748
of beta-2-adrenergic drugs, A752
bidisomide, A749
bioavailability of drugs with nonlinear pharmacokinetics, 1141
caffeine clearance, diurnal effect on, 184
cardiac transplantation and cyclosporine therapy effects on pharmacokinetics of digoxin, 338
cefpiromine in healthy volunteers, 256
cefprozil interactions with food, propantheline, metoclopramide, and probenecid in healthy volunteers, 725
cefprozil oral absolute bioavailability and intravenous dose-proportionality, 798
cimetidine effect on pirmenol pharmacokinetics, 91
cisplatin subcellular biodistribution in tumored rats, A747
clarithromycin in healthy young and elderly volunteers, 1045
cyclosporin-A pharmacokinetic parameters, arithmetic versus harmonic mean values for, 911
didanosine plasma concentrations in patients with AIDS or AIDS-related complex, 242
dosage regimen design, 210, 597
flurbiprofen in rat, A758
fluvastatin after single and multiple doses in normal volunteers, 630
gallium nitrate, A748
ganciclovir in liver transplantation patients, A753
genetic aspects of drug disposition and therapeutics, 107
glyceryl trinitrate time-dependent release, 77
heparin, 584
HP 749, A752
ibuprofen and acetaminophen pharmacokinetics in febrile children, 231
ibuprofen enantiomers, effect of food or sucralfate on bioavailability of, 1110
isosorbide-5-mononitrate, headache in healthy men and, A754
isosorbide-5-mononitrate bioavailability and pharmacokinetics in healthy volunteers, 553
lorazepam single-dose bioavailability of solution and tablet formulations, A748
lovastatin, 136
metformin bioavailability in tablet form, A757
moricizine in renal disease, A749
moricizine in renal insufficiency, 412
moricizine in young and healthy subjects, A754
naproxen tablets and suspension in children, A758
nefazodone in healthy volunteers and hepatic impairment, A756
nisoldipine, 571
nisoldipine coat-core tablets in hypertensive patients, A754
nizatidine, ranitidine, and cimetidine effects on pharmacokinetics of theophylline in COPD, 476
pentoxifylline in smokers and nonsmokers, 1054
pharmacokinetics and effects in healthy subjects, intraindividual variability in, 324
pravastatin, 136
pravastatin and metabolites in patients with renal impairment, 124
prednisolone, tenidap effects on, 222
prednisolone after intravenous and oral administration, A750
prednisolone and hydrocortisone interactions and, A756
principles of, in clinical medicine, 118
prohormone atrial natriuretic peptides amino acids 1-98, 31-67, and atrial natriuretic factor pharmacokinetics during and after rapid right ventricular pacing in dogs, 415
quinapril and quinaprilat in patients with various degrees of renal function, 344
in renal disease, A758
simvastatin, 136
sotalol enantiomers, 1105
sulindac, cholestyramine effects on, A754
tandospirone, ascending single doses in healthy volunteers, A751
tranexamic acid in patients with ulcerative colitis and healthy volunteers, 49
venlafaxine and its O-desmethyl metabolite, 716
verapamil, diltiazem and labetalol effects on bioavailability and metabolism of imipramine, 176
vinorelbine alone and combined with cisplatin, 1096
Phenindamine
sedative properties in healthy volunteers, A750
Physicians
in industry, 389
Pirmenol
pharmacokinetics, cimetidine effects on, 91
Platelet-Activating Factor
in sickle cell disease, A754
Platelet Aggregation
in patients with atherosclerosis, 133
Pravastatin
pharmacokinetics, 136
pharmacokinetics in patients with renal impairment, 124
Praziquantel
in neurocysticercosis, one-day dosage regimen for, A762
Prednisolone
pharmacokinetic interactions with hydrocortisone, A756
pharmacokinetics and pharmacodynamics after intravenous and oral administration of, A750
tenidap effects on pharmacokinetics and pharmacodynamics of, 222
Premenstrual Syndrome
busipirone efficacy and pharmacologic mechanism in, A748
Probenecid
pharmacokinetic interactions with cefprozil, 725
Prohormone Atrial Natriuretic Peptides
amino acids 1-98, 31-67, and atrial natriuretic factor pharmacokinetics during and after rapid right ventricular pacing in dogs, 415
Propantheline
pharmacokinetic interactions with cefprozil, 725
Propionic acids, 317
Propranolol
metabolism of, effects of diltiazem versus cimetidine on, 1099
Prostaglandin E_2
skin flap survival and, A763
Pulmonary Disease
nizatidine, ranitidine, and cimetidine effects on pharmacokinetics of theophylline in COPD, 476
omeprazole effects on theophylline elimination kinetics, 470
triamcinolone acetonide aerosol in asthma, 463
Pyrazinoylguanidine
antihypertensive, hypercholesterolemic, and renin effects of, 1128

Quazepam
kinetics, brain uptake, and lipid solubility of quazepam and its metabolites, A763
Quinapril
pharmacokinetics in patients with various degrees of renal function, 344
regional blood flow and cardiac function in patients with congestive heart failure, 70
Quinaprilat
pharmacokinetics in patients with various degrees of renal function, 344

Racemic Drugs
bioequivalency of, 915, 935, 955
Ramipril
ambulatory blood pressure effects of, A747
Ranitidine
droxicam pharmacokinetics and, 1115
theophylline pharmacokinetics in COPD, 476
Raynaud's Phenomenon
beta-blocking drug effects on peripheral circulation in, 652
Regulation
approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States, 889
regulatory requirements for generic chiral drugs and, 953
sharing costs of, 867
Renal Function. *See also* **Hemodialysis**
dopamine effects on, A742
dopaminergic agonist effects on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients, 55
erythropoietin dosing, response to, and effectiveness in end stage renal disease, A758
gabapentin disposition and, A751
geriatrics nephrology, 310
ketoprofen disposition and, A751
moricizine pharmacokinetics and, A749
moricizine pharmacokinetics in renal insufficiency, 412
naftopidil and ketanserin effects on aqueous humor dynamics and, A756
nitrendipine and, 284
pharmacokinetics in renal disease, A758
pravastatin and metabolite pharmacokinetics in patients with renal impairment, 124
quinapril and quinaprilat pharmacokinetics, 344
Renin-Angiotensin System
dopaminergic agonist effects on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients, 55
Retinoids
in cancer treatment, 868
Rheumatology
2-arylproprionic acid enantiomers and, 944

Schizophrenia
dopamine antagonists in, need for antiparkinsonian drugs and, A766
Sepsis
endotoxemia induced, histamine antagonist hemodynamic actions during, A745

Sertraline
lithium steady-state concentrations or renal clearance in healthy volunteers, 643
Sickle Cell Disease
platelet-activating factor in, A754
Simvastatin
benzafibrate with, in healthy subjects, 422
pharmacokinetics, 136
Skin Flaps
pentoxifylline and prostaglandin E_2 and survival of, A763
Sodium Nitrite
antidotal action against cyanide poisoning, 368
Sodium Thiosulfate
antidotal action against cyanide poisoning, 368
Sotalol
enantiomers of, pharmacokinetics of, 1105
Spinal Cord Injury
baclofen pharmacokinetics and pharmacodynamics in, A748
Status Epilepticus
grand mal, 215
Stereochemistry. *See* **Chirality**
Sulindac
cholestyramine effects on pharmacokinetics of, A754
Supraventricular Tachycardia
naldolol pharmacokinetics in children with, 1023
Synthroid
excess ingestion presenting as congestive heart failure, 18
levothyroxine absorption from, 1135

Tandospirone
pharmacokinetics and pharmacodynamics of ascending single doses in healthy volunteers, A751
Tenidap
prednisolone pharmacokinetics and pharmacodynamics, 222
Terazosin, 520
in benign prostatic hyperplasia, quality of life assessment and, A760
in benign prostatic hyperplasia, safety and efficacy of, A759, A762
blood pressure and urinary output of dopamine in hypertensive patients and, 816
blood pressure response and safety of, A744
in essential hypertension, concomitant administration of methyclothiazide and, 351
in hypertension, effect of age and dose on incidence of adverse effects, 434
Terfenadine
pharmacokinetics in healthy elderly subjects, 267
in seasonal allergic rhinitis, onset of action of, A761
Theophylline
omeprazole effects on elimination kinetics, 470
saliva and serum concentrations of, A754
Therapeutic Reviews
acute myelogenous leukemia, new drugs in, 296
antiarrhythmic actions, classification of, 969
biomodulators in cancer treatment, 2
hematopoietic growth factors, 486
heparin pharmacokinetics, clinical indications, and adverse effects, 584
opiate antagonists and eating behavior, 1060
oral anticoagulant pharmacodynamics, clinical indications and adverse effects, 196
retinoids in cancer treatment, 868
unstable angina, pharmacotherapy of, 390
Thrombolytic Agents
comparisons of, A762
Tranexamic Acid
pharmacokinetics in patients with ulcerative colitis and healthy volunteers, 49
Transcranial Doppler
antihypertensive medication, evaluation of effects on cerebral blood flow velocity, 66
Triamcinolone Acetonide
aerosol, in asthma, 463

UDP-Glucuronosyltransferase
mouse, molecular cloning of, A762
Ulcerative Colitis
tranexamic acid pharmacokinetics in, 49
Urinary Tract Infections
candidal, single-dose intravenous amphotericin B in, A750
Urokinase
in central venous dialysis access malfunction, continuous infusion of, A757

Valproate
circadian changes depending on meal condition and, 822
Valproic Acid
cholestyramine reduction of serum concentrations of, A754
Venlafaxine
pharmacokinetics, 716
Ventricular Dilation
in compromised myocardium, control of, 680
Ventricular Tachycardia
amiodarone in, A743
beta-blockers added to antiarrhythmic drugs in inducible sustained ventricular tachycardia, A743
Verapamil
age-selective stereoselective disposition, A751
atrial natriuretic factors and renin-angiotensin-aldosterone-vasopressin system and, 1120
concentration/effect analysis of, A752
imipramine bioavailability and metabolism, 176
in mild to moderate hypertension, A744
nifedipine combined with, in hypertension, A744
in office and ambulatory settings, 564
sustained-release formulations for hypertension, 455
Vinorelbine
pharmacokinetics, 1096
Volume Overload
atrial natriuretic factors and renin-angiotensin-aldosterone-vasopressin system and, 1120
Vulvovaginal Candidiasis
pathogen evolution in, 248

Warfarin
moricizine effects on pharmacokinetics and pharmacodynamics in healthy volunteers, 558

Zolpidem
benzodiazepine binding of, A764
Zopiclone
benzodiazepine binding of, A764